Five-year Results Of The GORE® EXCLUDER® Iliac Branch Endoprosthesis Pivotal U.S. Multicenter Study Confirm Safety, Efficacy and Durability
FLAGSTAFF, Ariz., Aug. 19, 2021 /PRNewswire/ -- W. L. Gore & Associates (Gore), today announced that five-year results of the U.S. prospective, multicenter study (N = 63) of endovascular repair of iliac aneurysms using the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) were presented at the 2021 Society for Vascular Surgery Annual Meeting. Results of the study confirmed the safety, efficacy and durability of the IBE for treatment of aortoiliac and iliac artery aneurysms.
Approved by the U.S. Food & Drug Administration (FDA) in February 2016, the GORE EXCLUDER Iliac Branch Endoprosthesis was the first off-the-shelf aortic branch device approved in the U.S. and remains the only device indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms.
Five-year primary patency of the internal iliac artery and external iliac artery IBE limbs was 95.1% and 100%, respectively. Furthermore, no patients experienced new onset buttock claudication on the IBE side or new onset erectile dysfunction. Additionally, there were no Type I or Type III endoleaks and no device migrations identified by the core lab, and freedom from secondary intervention was 88.2%. The device offers a treatment option that allows patients the benefits of endovascular therapy yet preserves pelvic perfusion.
"The positive outcomes from this five-year study validate the effectiveness and durability of the GORE EXCLUDER Iliac Branch Endoprosthesis for the treatment of iliac artery aneurysms," said Darren B. Schneider, M.D., the study National Principal Investigator and Chief of Vascular Surgery and Endovascular Therapy at Penn Medicine and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. "Importantly, the IBE reduces the risk of common iliac artery enlargement and rupture while maintaining patency of the internal iliac artery to prevent complications associated with internal iliac artery sacrifice."
Used in conjunction with the GORE® EXCLUDER AAA Endoprosthesis, the IBE isolates the common iliac artery from systemic blood flow and preserves blood flow in the external iliac and internal iliac arteries. Its design allows for a two-staged repositionable deployment for precise placement and has a pre-cannulated internal iliac gate and bi-femoral delivery for ease-of-use.
The GORE EXCLUDER Iliac Branch Endoprosthesis is part of the continually growing GORE EXCLUDER Device family and GORE® TAG® Devices that share a mission to effectively treat aortic aneurysms through minimally invasive means, backed by Gore's highly rated clinical support team and comprehensive educational offerings.
For more information on the GORE EXCLUDER Iliac Branch Endoprosthesis and the GORE EXCLUDER Device family, visit goremedical.com.*
* For complete indications and other important safety information for Gore commercial products referenced herein, refer to the applicable Instructions for Use (IFU).
About Gore
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Since 1958, Gore has solved complex technical challenges in demanding environments — from outer space to the world's highest peaks to the inner workings of the human body. With more than 11,000 Associates and a strong, team-oriented culture, Gore generates annual revenues of $3.8 billion. For more information, visit gore.com.
Products listed may not be available in all markets.
GORE, Together, improving life, EXCLUDER and TAG are trademarks of W. L. Gore & Associates. 21217403-EN August 2021
SOURCE W. L. Gore & Associates
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article